Abstract MPTU11: Prediabetes Progression In Young American Adults: A Pooling Project

Introduction: There is growing clinical concern about increases in prediabetes and type 2 diabetes in young adults. Novel weight-loss medications, e.g., glucagon-like peptide-1-receptor agonist (GLP1-RA), can prevent progression from prediabetes to diabetes. Characterizing risk and risk factors for progression to diabetes could help identify high-risk subgroups to prioritize for intensive lifestyle interventions and novel medications in the growing population of young adults with prediabetes. Objective: To characterize 5-year risk and risk factors for progression from prediabetes to diabetes in adults <40 years. Methods: We pooled and harmonized data from participants aged 18 to 40 years with prediabetes (fasting glucose FG 100-125 mg/dL) from three cohorts (HCHS/SOL, CARDIA, FHS-Gen3). We used Poisson regression to estimate 5-year risk and age- and cohort-adjusted rate ratios (95%CI) for incident diabetes (FG ≥126 mg/dL or medication use), overall and according to demographics, FG categories (FG 100-109 mg/dL,110-125 mg/dL), and GLP1-RA eligibility criteria for weight loss (body mass index ≥30 kg/m 2 or body mass index ≥27 kg/m 2 with dyslipidemia or hypertension) during a median follow-up of 6.2 years. Results: The 610 young adults with prediabetes had a mean age of 32 (SD, 6) years, 32% were women, and 38% self-identified as Hispanic/Latino. The 5-year risk of progression from prediabetes to diabetes was 8.7% (95%CI: 6.6, 10.8) ( Table ). The 5-year risk of diabetes for young adults with prediabetes who met GLP-1RA eligibility criteria for weight loss was 14.0% (95% CI: 9.9, 18.1), and for those with FG between 110 to 125 mg/dL was 21.5% (95% CI: 14.1, 29.0). The 5-year risk of diabetes was highest for young adults who met GLP1-RA eligibility criteria and FG between 110 to 125 mg/dL (36.1%), which was ~5-times (95% CI: 2.8, 8.6) the risk for those meeting neither criteria. Conclusion: In young adults with prediabetes, we identified subgroups with elevated risk of progression, with a 5-year diabetes risk of 33% in the highest risk group. This highlights opportunities for targeted approaches for intensive lifestyle and pharmacologic interventions for diabetes prevention.